Reuters logo
in 2 months
BRIEF-Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy
June 7, 2017 / 11:46 AM / in 2 months

BRIEF-Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy

June 7 (Reuters) - Sangamo Therapeutics:

* Sangamo Therapeutics and Pfizer announce that SB-525 investigational hemophilia A gene therapy receives orphan medicinal product designation from the European medicines agency

* Cos also announce Phase 1/2 clinical trial evaluating SB-525 in adults with severe hemophilia A is now open for enrollment

* Sangamo Therapeutics Inc - initial data from study of SB-525 in adults with hemophilia A expected in late 2017 or early 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below